TY - JOUR
T1 - Specificity of vascular endothelial growth factor treatment for radiation necrosis
AU - Perez-Torres, Carlos J.
AU - Yuan, Liya
AU - Schmidt, Robert E.
AU - Rich, Keith M.
AU - Drzymala, Robert E.
AU - Hallahan, Dennis E.
AU - Ackerman, Joseph J.H.
AU - Garbow, Joel R.
N1 - Publisher Copyright:
© 2015 Elsevier Ireland Ltd.
PY - 2015/11/1
Y1 - 2015/11/1
N2 - Recently, radiation induced necrosis in the brain has been treated using bevacizumab, an anti-VEGF antibody. We validated the VEGF specificity by comparing the therapeutic efficacy of anti-VEGF with non-specific isotype control antibody. Additionally, we found that VEGF over-expression and RN developed simultaneously, which precludes preventative anti-VEGF treatment.
AB - Recently, radiation induced necrosis in the brain has been treated using bevacizumab, an anti-VEGF antibody. We validated the VEGF specificity by comparing the therapeutic efficacy of anti-VEGF with non-specific isotype control antibody. Additionally, we found that VEGF over-expression and RN developed simultaneously, which precludes preventative anti-VEGF treatment.
KW - Magnetic resonance imaging
KW - Radiation necrosis
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=84952636728&partnerID=8YFLogxK
U2 - 10.1016/j.radonc.2015.09.004
DO - 10.1016/j.radonc.2015.09.004
M3 - Article
C2 - 26376163
AN - SCOPUS:84952636728
SN - 0167-8140
VL - 117
SP - 382
EP - 385
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
IS - 2
ER -